Genetic Diagnosis of Hepatic Steatosis
AssigneeBoard of Regents, The University of Texas System
InventorsHelen H. Hobbs, Jonathan C. Cohen
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of identifying a genetic variant in a person determined to have or be predisposed having a fatty liver by determining whether the person has PNPLA3-I148M. Also disclosed are methods of identifying a genetic variant in a person by determining whether the person has PNPLA3-I148M; and prescribing to the person a treatment to reduce liver fat or associated inflammation.
Claims21
1-50. (canceled)
A method for determining a genetic marker and treating a human, the method comprising steps:
- (a) determining that the genome of the human comprises a marker of PNPLA3-I148M that is SNP rs738409(G);
- and based thereon,
- (b) treating the person with an antiobesity drug that is orlistat, sibutramine, exenatide, pramlintide or rimonabant.
A method for determining a genetic marker and treating a human, the method comprising steps:
- (a) determining that the genome of the human comprises a marker of PNPLA3-I148M that is SNP rs738409(G);
- and based thereon,
- (b) treating the person with an anti-diabetic drug that is a thiazolidinedione, metformin or glimepiride.
Dependencies are inferred from the claim text.